Break it Down: Orthocell’s pivotal path into US healthcare market

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Orthocell’s (ASX:OCC) nerve repair product deemed safe and effective for use in the surgical repair of peripheral nerves.

A study successfully met all end points, making way for the company to lodge an FDA submission to commercially distribute Remplir™ into a growing US$1.6B market.

Tune in to get the latest.

While Orthocell is a Stockhead advertiser, it did not sponsor this content.